title: A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model.
abstract: BACKGROUND
  Tumor cell interactions with the microenvironment, especially those of bone-marrow-derived myeloid cells, are important in various aspects of tumor metastasis. Myeloid-derived suppressor cells (MDSCs) have been suggested to constitute tumor-favoring microenvironments. In this study, we elucidated a novel mechanism by which the MDSCs can mediate spontaneous distant metastasis of breast cancer cells.
  
  
  METHODS
  Murine breast cancer cells, 4T1 and EMT6, were orthotopically grafted into the mammary fat pads of syngeneic BALB/c mice. CD11b(+)Gr-1(+) MDSCs in the spleen, liver, lung and primary tumor mass were analyzed. To evaluate the role of MDSCs in the distant metastasis, MDSCs were depleted or reconstituted in tumor-bearing mice. To evaluate whether MDSCs in the metastasizing tumor microenvironment affect breast cancer cell behavior, MDSCs and cancer cells were co-cultivated. To investigate the role of MDSCs in in vivo metastasis, we blocked the interactions between MDSCs and cancer cells.
  
  
  RESULTS
  Using a murine breast cancer cell model, we showed that murine breast cancer cells with high IL-6 expression recruited more MDSCs and that the metastasizing capacity of cancer cells paralleled MDSC recruitment in tumor-bearing mice. Metastasizing, but not non-metastasizing, tumor-derived factors induced MDSCs to increase IL-6 production and full activation of recruited MDSCs occurred in the primary tumor site and metastatic organ in the vicinity of metastasizing cancer cells, but not in lymphoid organs. In addition, tumor-expanded MDSCs expressed Adam-family proteases, which facilitated shedding of IL-6 receptor, thereby contributing to breast cancer cell invasiveness and distant metastasis through IL-6 trans-signaling. The critical role of IL-6 trans-signaling was confirmed in both the afferent and efferent pathways of metastasis.
  
  
  CONCLUSIONS
  In this study, we showed that metastasizing cancer cells induced higher MDSCs infiltration and prompted them to secret exaggerated IL-6 as well as soluble IL-6Ra, which, in turn, triggered a persistent increase of pSTAT3 in tumor cells. This potential tumor-MDSC axis involving IL-6 trans-signaling directly affected breast cancer cell aggressiveness, leading to spontaneous metastasis.
authors.forename: Keunhee
authors.initials: K
authors.lastname: Oh
authors.forename: Ok-Young
authors.initials: OY
authors.lastname: Lee
authors.forename: Suh Youn
authors.initials: SY
authors.lastname: Shon
authors.forename: Onyou
authors.initials: O
authors.lastname: Nam
authors.forename: Po Mee
authors.initials: PM
authors.lastname: Ryu
authors.forename: Myung Won
authors.initials: MW
authors.lastname: Seo
authors.forename: Dong-Sup
authors.initials: DS
authors.lastname: Lee
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000473:pathology*; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D005260:Female; D015850:Interleukin-6 / Q000378:metabolism*; D053698:Interleukin-6 Receptor alpha Subunit / Q000097:blood / Q000378:metabolism*; D051379:Mice; D022423:Myeloid Cells / Q000276:immunology / Q000378:metabolism*; D009362:Neoplasm Metastasis; D010766:Phosphorylation; D050796:STAT3 Transcription Factor / Q000378:metabolism; D015398:Signal Transduction; D047368:Tumor Burden; D059016:Tumor Microenvironment / Q000276:immunology
chemical_list: D015850:Interleukin-6; D053698:Interleukin-6 Receptor alpha Subunit; D050796:STAT3 Transcription Factor
references.citation: Cancer Res. 2005 Apr 1;65(7):2532-6
references.pmid: 15805244
references.citation: J Clin Invest. 2007 Dec;117(12):3988-4002
references.pmid: 18060036
references.citation: J Immunol. 2010 Mar 15;184(6):3106-16
references.pmid: 20142361
references.citation: Clin Cancer Res. 2011 Oct 1;17(19):6125-9
references.pmid: 21685479
references.citation: Cancer Res. 2010 Dec 15;70(24):10161-9
references.pmid: 21159638
references.citation: J Clin Invest. 2006 Oct;116(10):2777-90
references.pmid: 17016559
references.citation: Nat Cell Biol. 2006 Dec;8(12):1369-75
references.pmid: 17128264
references.citation: Crit Rev Oncol Hematol. 2011 Dec;80(3):433-49
references.pmid: 21330148
references.citation: Cancer Res. 2010 Aug 1;70(15):6139-49
references.pmid: 20631080
references.citation: J Clin Invest. 2010 Feb;120(2):457-71
references.pmid: 20093776
references.citation: Cancer Cell. 2008 Nov 4;14(5):408-19
references.pmid: 18977329
references.citation: J Exp Med. 2011 Aug 1;208(8):1707-19
references.pmid: 21746810
references.citation: Cancer Cell. 2009 Feb 3;15(2):91-102
references.pmid: 19185844
references.citation: Biochim Biophys Acta. 2010 Feb;1803(2):234-45
references.pmid: 20026129
references.citation: Cancer Res. 2009 Jul 1;69(13):5514-21
references.pmid: 19549903
references.citation: Cancer Res. 2011 Dec 15;71(24):7433-41
references.pmid: 22006996
references.citation: Nat Rev Cancer. 2003 Jun;3(6):453-8
references.pmid: 12778135
references.citation: Cancer Res. 2012 Feb 15;72(4):876-86
references.pmid: 22174368
references.citation: Oncol Rep. 2012 Aug;28(2):453-8
references.pmid: 22614133
references.citation: Immunol Rev. 2008 Apr;222:180-91
references.pmid: 18364002
references.citation: Nat Rev Immunol. 2009 Mar;9(3):162-74
references.pmid: 19197294
references.citation: J Immunol. 2008 Jun 1;180(11):7102-6
references.pmid: 18490707
references.citation: Blood. 2007 Sep 15;110(6):1748-55
references.pmid: 17567983
references.citation: Blood. 2002 Nov 1;100(9):3175-82
references.pmid: 12384415
references.citation: Cancer Res. 2005 Dec 15;65(24):11743-51
references.pmid: 16357187
references.citation: Nature. 2009 Jan 1;457(7225):102-6
references.pmid: 19122641
references.citation: Clin Cancer Res. 2007 Nov 1;13(21):6459-68
references.pmid: 17975158
references.citation: Cancer Immunol Immunother. 2009 Jan;58(1):49-59
references.pmid: 18446337
references.citation: Cancer Cell. 2009 Feb 3;15(2):103-13
references.pmid: 19185845
references.citation: J Exp Med. 2010 Oct 25;207(11):2439-53
references.pmid: 20876310
references.citation: Cancer Res. 2011 Jan 15;71(2):424-34
references.pmid: 21123455
references.citation: Mol Cancer Res. 2011 Dec;9(12):1658-67
references.pmid: 21976712
references.citation: Cancer Lett. 2010 Sep 1;295(1):110-23
references.pmid: 20236757
references.citation: Cell. 2010 Jan 22;140(2):197-208
references.pmid: 20141834
references.citation: Eur J Immunol. 2011 Mar;41(3):749-59
references.pmid: 21287554
references.citation: Nat Immunol. 2006 Dec;7(12):1299-308
references.pmid: 17086187
references.citation: J Immunol. 2010 Feb 1;184(3):1543-51
references.pmid: 20042582
references.citation: Cell. 2004 Jun 25;117(7):927-39
references.pmid: 15210113
references.citation: Cancer Cell. 2012 May 15;21(5):642-654
references.pmid: 22624714
references.citation: Cell. 2012 Jul 6;150(1):165-78
references.pmid: 22770218
references.citation: Breast Cancer Res. 2011 Oct 03;13(5):R96
references.pmid: 21967801
references.citation: Cancer Cell. 2011 Apr 12;19(4):456-69
references.pmid: 21481788
references.citation: PLoS One. 2011;6(5):e19938
references.pmid: 21603616
references.citation: Eur J Cell Biol. 2011 Jun-Jul;90(6-7):484-94
references.pmid: 21145125
references.citation: J Immunol. 2008 Sep 1;181(5):3291-300
references.pmid: 18714001
references.citation: Cancer Res. 2011 Jan 15;71(2):614-24
references.pmid: 21224357
references.citation: J Clin Invest. 2011 Oct;121(10):3804-9
references.pmid: 21965337
references.citation: Cytokine. 2012 Aug;59(2):228-36
references.pmid: 22595649
references.citation: J Immunother. 2012 Feb-Mar;35(2):107-15
references.pmid: 22306898
references.citation: FASEB J. 2007 Nov;21(13):3763-70
references.pmid: 17586727
references.citation: Immunol Rev. 2008 Apr;222:162-79
references.pmid: 18364001
references.citation: J Natl Cancer Inst. 2012 Jul 18;104(14):1068-79
references.pmid: 22767204
references.citation: Nat Rev Immunol. 2012 Mar 22;12(4):253-68
references.pmid: 22437938